Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
Identifieur interne : 000078 ( Main/Merge ); précédent : 000077; suivant : 000079Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
Auteurs : Nir Giladi [Israël] ; Liesbet Ghys [Belgique] ; Erwin Surmann [Allemagne] ; Babak Boroojerdi [États-Unis] ; Joseph Jankovic [États-Unis]Source :
- Parkinsonism & related disorders ; 2014.
English descriptors
- KwdEn :
- Administration, Cutaneous, Adult, Age Factors, Aged, Aged, 80 and over, Antiparkinson Agents (administration & dosage), Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Dyskinesias (diagnosis), Dyskinesias (epidemiology), Dyskinesias (etiology), Female, Humans, Kaplan-Meier Estimate, Levodopa (therapeutic use), Longitudinal Studies, Male, Middle Aged, Parkinson Disease (drug therapy), Sex Factors, Tetrahydronaphthalenes (administration & dosage), Thiophenes (administration & dosage).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Tetrahydronaphthalenes, Thiophenes.
- diagnosis : Dyskinesias.
- drug therapy : Parkinson Disease.
- epidemiology : Dyskinesias.
- etiology : Dyskinesias.
- chemical , therapeutic use : Levodopa.
- Administration, Cutaneous, Adult, Age Factors, Aged, Aged, 80 and over, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Longitudinal Studies, Male, Middle Aged, Sex Factors.
Abstract
In two 6-month, double-blind, placebo-controlled studies, rotigotine transdermal system was well-tolerated and efficacious monotherapy in early-stage PD. This post hoc analysis of the long-term open-label extensions (NCT00594165; NCT00599196) of these studies assessed incidence and severity of dyskinesia in participants treated with rotigotine, with or without concomitant levodopa, for up to 6 years.
DOI: 10.1016/j.parkreldis.2014.09.016
PubMed: 25444083
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000019
- to stream PubMed, to step Curation: 000019
- to stream PubMed, to step Checkpoint: 000036
- to stream Ncbi, to step Merge: 000478
- to stream Ncbi, to step Curation: 000478
- to stream Ncbi, to step Checkpoint: 000478
Links to Exploration step
pubmed:25444083Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.</title>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel; Sago School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: nirg@tlvmc.gov.il.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel; Sago School of Neuroscience, Tel-Aviv University, Tel-Aviv</wicri:regionArea>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ghys, Liesbet" sort="Ghys, Liesbet" uniqKey="Ghys L" first="Liesbet" last="Ghys">Liesbet Ghys</name>
<affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Surmann, Erwin" sort="Surmann, Erwin" uniqKey="Surmann E" first="Erwin" last="Surmann">Erwin Surmann</name>
<affiliation wicri:level="1"><nlm:affiliation>UCB Pharma, Monheim am Rhein, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>UCB Pharma, Monheim am Rhein</wicri:regionArea>
<wicri:noRegion>Monheim am Rhein</wicri:noRegion>
<wicri:noRegion>Monheim am Rhein</wicri:noRegion>
<wicri:noRegion>Monheim am Rhein</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boroojerdi, Babak" sort="Boroojerdi, Babak" uniqKey="Boroojerdi B" first="Babak" last="Boroojerdi">Babak Boroojerdi</name>
<affiliation wicri:level="2"><nlm:affiliation>UCB Biosciences Inc., Raleigh, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>UCB Biosciences Inc., Raleigh, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25444083</idno>
<idno type="pmid">25444083</idno>
<idno type="doi">10.1016/j.parkreldis.2014.09.016</idno>
<idno type="wicri:Area/PubMed/Corpus">000019</idno>
<idno type="wicri:Area/PubMed/Curation">000019</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000036</idno>
<idno type="wicri:Area/Ncbi/Merge">000478</idno>
<idno type="wicri:Area/Ncbi/Curation">000478</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000478</idno>
<idno type="wicri:Area/Main/Merge">000078</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.</title>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel; Sago School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: nirg@tlvmc.gov.il.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel; Sago School of Neuroscience, Tel-Aviv University, Tel-Aviv</wicri:regionArea>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ghys, Liesbet" sort="Ghys, Liesbet" uniqKey="Ghys L" first="Liesbet" last="Ghys">Liesbet Ghys</name>
<affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Surmann, Erwin" sort="Surmann, Erwin" uniqKey="Surmann E" first="Erwin" last="Surmann">Erwin Surmann</name>
<affiliation wicri:level="1"><nlm:affiliation>UCB Pharma, Monheim am Rhein, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>UCB Pharma, Monheim am Rhein</wicri:regionArea>
<wicri:noRegion>Monheim am Rhein</wicri:noRegion>
<wicri:noRegion>Monheim am Rhein</wicri:noRegion>
<wicri:noRegion>Monheim am Rhein</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boroojerdi, Babak" sort="Boroojerdi, Babak" uniqKey="Boroojerdi B" first="Babak" last="Boroojerdi">Babak Boroojerdi</name>
<affiliation wicri:level="2"><nlm:affiliation>UCB Biosciences Inc., Raleigh, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>UCB Biosciences Inc., Raleigh, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Parkinsonism & related disorders</title>
<idno type="e-ISSN">1873-5126</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term>
<term>Adult</term>
<term>Age Factors</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dyskinesias (diagnosis)</term>
<term>Dyskinesias (epidemiology)</term>
<term>Dyskinesias (etiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Levodopa (therapeutic use)</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Sex Factors</term>
<term>Tetrahydronaphthalenes (administration & dosage)</term>
<term>Thiophenes (administration & dosage)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Tetrahydronaphthalenes</term>
<term>Thiophenes</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term>
<term>Adult</term>
<term>Age Factors</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Sex Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In two 6-month, double-blind, placebo-controlled studies, rotigotine transdermal system was well-tolerated and efficacious monotherapy in early-stage PD. This post hoc analysis of the long-term open-label extensions (NCT00594165; NCT00599196) of these studies assessed incidence and severity of dyskinesia in participants treated with rotigotine, with or without concomitant levodopa, for up to 6 years.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000078 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000078 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= JankovicV1 |flux= Main |étape= Merge |type= RBID |clé= pubmed:25444083 |texte= Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:25444083" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a JankovicV1
![]() | This area was generated with Dilib version V0.6.19. | ![]() |